Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures
Kinarus Therapeutics Holding AG / Key word(s): Annual Results Ad hoc announcement pursuant to Art. 53 LR |
- Audited full year 2022 annual financial figures due to be reported by end of May 2023
Basel, Switzerland, May 5, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today reported unaudited key financial figures for the year ended 31 December 2022 of Kinarus Therapeutics Group. The audited full year 2022 financial figures are due to be reported by end of May 2023
On 28 April 2023, Kinarus announced that the SIX Exchange Regulation ("SER") approved a deadline extension until the end of May 2023 for the publication of the Kinarus’ 2022 annual report. In its decision, SER asked Kinarus to report unaudited key financial figures for the consolidated financial statements of Kinarus Therapeutics Group for the year ended 31 December 2022 by 5 May 2023. In compliance with SER’s request, Kinarus reported the following figures which have been prepared on a going concern basis.
Unaudited Key Financial Figures for the Year Ended 31 December 2022 for the Consolidated Financial Statements of Kinarus Therapeutics Group
|
TCHF |
Loss before financial result, taxes, depreciation and amortization |
(318) |
Loss before taxes |
(39,899) |
Net loss |